$1.2 B

ITCI Mkt cap, 14-Jun-2018
Intra-Cellular Therapies Net income (Q1, 2018)-35.5 M
Intra-Cellular Therapies EBIT (Q1, 2018)-37.1 M
Intra-Cellular Therapies Cash, 31-Mar-201874.4 M

Intra-Cellular Therapies Revenue Breakdown

Embed Graph

Intra-Cellular Therapies revenue breakdown by business segment: 33.6% from License and collaboration revenue and 66.4% from Grant Revenue

Intra-Cellular Therapies Financials

Intra-Cellular Therapies Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

2.7 m577.3 k91.4 k330.7 k245.8 k

Revenue growth, %

(79%)(84%)262%

R&D expense

21.2 m87.7 m93.8 m79.4 m

General and administrative expense

10.3 m18.2 m24.8 m23.7 m

Operating expense total

31.6 m105.9 m118.6 m103.1 m

EBIT

(26.3 m)(31 m)(105.8 m)(118.3 m)(102.8 m)

EBIT margin, %

(960%)(5368%)(115816%)(35760%)(41833%)

Interest expense

613 k7.1 k36.8 k

Interest income

29.6 k303.9 k1 m2.9 m4 m

Pre tax profit

(30.7 m)(104.8 m)(115.4 m)

Income tax expense

(18 k)1.6 k1.6 k1.1 m(1.1 m)

Net Income

(26.9 m)(30.7 m)(104.8 m)(116.4 m)(97.8 m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

668 k167.8 k219.2 k124.4 k3.3 k57.4 k124.4 k3.3 k228.4 k4.4 k95.3 k114.7 k

R&D expense

4.2 m2.8 m2.7 m4 m18.6 m17.8 m28.5 m23.4 m25.3 m23.9 m21.5 m12.5 m30.7 m

General and administrative expense

1.3 m1.9 m2.1 m2.6 m3.8 m4 m3.9 m5.1 m6.5 m6.3 m6.3 m6.3 m6.4 m

Operating expense total

5.5 m4.7 m4.8 m6.6 m22.4 m21.7 m32.3 m28.5 m31.8 m30.2 m27.8 m18.7 m37.1 m

EBIT

(4.8 m)(4.6 m)(4.6 m)(6.5 m)(22.4 m)(21.7 m)(32.3 m)(28.5 m)(31.5 m)(30.2 m)(27.8 m)(18.6 m)(37.1 m)

EBIT margin, %

(716%)(2726%)(2103%)(5227%)(675739%)(37796%)(26001%)(859664%)(13808%)(691985%)(29127%)(16227%)

Interest expense

131.9 k5 k2 k5 k2 k12.3 k

Interest income

5.6 k36.2 k80.1 k88.1 k113.9 k179.6 k188.9 k656.4 k709.6 k763.9 k822.2 k857.8 k1.6 m

Pre tax profit

(26.9 m)(17.8 m)(35.5 m)

Income tax expense

(832.6 k)1.6 k1.6 k

Net Income

(4.9 m)(4.5 m)(4.5 m)(6.4 m)(22.3 m)(21.5 m)(32.2 m)(27.8 m)(30.8 m)(30.3 m)(26.9 m)(17.8 m)(35.5 m)

Intra-Cellular Therapies Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

35.2 m61.3 m47.2 m48.6 m37.8 m

Accounts Receivable

336.3 k51.6 k30.7 k94.3 k

Inventories

762.2 k1.3 m8 m4 m

Current Assets

38.2 m131 m483.3 m388.2 m469.2 m

PP&E

68.3 k54.6 k775.5 k627.6 k1.1 m

Total Assets

38.4 m131.1 m484.1 m388.9 m471.5 m

Accounts Payable

3.4 m2.1 m1.6 m3.8 m6.2 m

Short-term debt

Current Liabilities

6.8 m10.6 m6.3 m10.5 m14.2 m

Long-term debt

Total Liabilities

13.4 m17 m

Additional Paid-in Capital

89.2 m208.9 m669.9 m685.3 m862.5 m

Retained Earnings

(57.6 m)(88.3 m)(193 m)(309.5 m)(407.2 m)

Total Equity

31.6 m120.6 m476.2 m375.5 m454.4 m

Financial Leverage

1.2 x1.1 x1 x1 x1 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

44.1 m143.6 m91.1 m68.9 m100.8 m71.4 m332.8 m37.2 m52 m200.4 m23.6 m29.6 m74.4 m

Accounts Receivable

251.3 k167.8 k219.2 k124.4 k3.3 k9.1 k51.6 k98.2 k1.3 k68.2 k61.9 k

Current Assets

47.1 m146.4 m141.2 m137.5 m236.5 m212.6 m512.3 m462.9 m446.8 m541.8 m371.6 m348.8 m443.2 m

PP&E

75.7 k65.1 k63.9 k57.4 k559.7 k722.1 k785.5 k731.4 k718.7 k677.7 k605.7 k628.9 k1.3 m

Total Assets

47.3 m146.6 m141.3 m137.6 m237.1 m213.4 m513.1 m463.7 m447.6 m542.6 m372.3 m349.5 m445.6 m

Accounts Payable

4 m2.1 m415.8 k503.9 k4.6 m4.9 m705 k2 m3.9 m5.4 m7.2 m1.8 m10 m

Current Liabilities

7.8 m3.9 m2.7 m3.6 m14.6 m9.3 m10.4 m8.9 m19.4 m140.7 m16.3 m7 m19.7 m

Total Liabilities

14.8 m9.8 m11.3 m10.9 m21.6 m143.3 m19.3 m9.9 m22.5 m

Additional Paid-in Capital

89.1 m204.8 m205.3 m207.2 m332.9 m335.7 m666.1 m673.7 m677.6 m681.5 m689.7 m694.1 m867.2 m

Retained Earnings

(49.5 m)(62.1 m)(66.6 m)(73.1 m)(110.5 m)(132.1 m)(164.2 m)(220.9 m)(251.7 m)(282 m)(336.4 m)(354.2 m)(442.7 m)

Total Equity

39.6 m142.7 m138.6 m134 m222.4 m203.6 m501.9 m452.7 m426 m399.3 m353 m339.7 m423.2 m

Financial Leverage

1.2 x1 x1 x1 x1.1 x1 x1 x1 x1.1 x1.4 x1.1 x1 x1.1 x

Intra-Cellular Therapies Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(30.7 m)(104.8 m)(116.4 m)(97.8 m)

Depreciation and Amortization

25.5 k139.6 k196.9 k213.9 k

Accounts Receivable

284.7 k20.9 k(63.7 k)94.3 k

Inventories

Accounts Payable

(1.3 m)(419.9 k)2.1 m2.4 m

Cash From Operating Activities

(22.8 m)(102.3 m)(91.3 m)(80.5 m)

Purchases of PP&E

(11.8 k)(860.6 k)(49 k)(723.4 k)

Cash From Investing Activities

(66.7 m)(361.8 m)92.3 m(92.7 m)

Cash From Financing Activities

115.7 m449.9 m477.7 k162.4 m

Interest Paid

7.1 k7.1 k36.8 k

Income Taxes Paid

45 k1 m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(4.9 m)(4.5 m)(4.5 m)(6.4 m)(22.3 m)(21.5 m)(32.2 m)(27.8 m)(30.8 m)(30.3 m)(26.9 m)(35.5 m)

Depreciation and Amortization

82.5 k

Accounts Receivable

219.2 k124.4 k3.3 k9.1 k51.6 k98.2 k1.3 k68.2 k

Accounts Payable

415.8 k503.9 k4.6 m4.9 m705 k2 m3.9 m5.4 m7.2 m3.9 m

Cash From Operating Activities

(27 m)

Purchases of PP&E

(295.1 k)

Cash From Investing Activities

63.3 m

Cash From Financing Activities

337.8 k

Intra-Cellular Therapies Ratios

USDY, 2018

Financial Leverage

1.1 x
Report incorrect company information

Intra-Cellular Therapies Operating Metrics

FY, 2017

Patents and Patent Applications

80
Report incorrect company information